An independent panel advising the US Food and Drug Administration (FDA) unanimously recommended the Johnson and Johnson Covid-19 vaccine for emergency use for all adults.
The news was announced by the Vaccines and Related Biological Products Advisory Committee (VRBPAC).
J&J shares traded in the low $160 (£116.4) per share range throughout the session in anticipation of the move. After opening Friday at $161.03, J&J shares reached as high as $616.81 shortly after the 2 pm EDT announcement. J&J shares closed Friday at $161.30, up 0.16%.
The non-binding 19-0 vote came one day after the same committee recommended the Moderna half-dose booster shot. The difference, however, is VRBPAC was broader in recommending the J&J booster for those aged 18 and up, rather than those 65 and older or at a higher risk of complications from Covid-19, and with a shorter, two-month wait from a recipient’s previous dose versus six months for the Moderna booster.
More announcements coming
The FDA is expected to authorise both the J&J and Moderna booster shots next week.
Meanwhile, the FDA delayed a decision on authorising the Moderna mRNA-1237 vaccine for adolescents aged 12 to 17, due to uncertainty over its risk of causing Myocarditis – an inflammation of the heart – the Wall Street Journal reported.
Moderna shares moved lower Friday, closing at $324.21, down 4.92% from the $341.01 opening share price.